Join us for this live virtual CME activity focused on the role of IDH and FLT3 mutations in acute myeloid leukemia (AML). Discover how these genetic alterations impact prognosis and shape targeted treatment strategies. Our expert faculty will present key clinical evidence for IDH1/2 inhibitors and FLT3-directed therapies, while addressing treatment sequencing and the integration of emerging options into practice. The discussion will also highlight precision medicine approaches and evidence-based strategies for managing patients with AML with actionable mutations.